[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566729":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":16,"studyPopulation":16,"armGroups":23,"interventions":35,"overallOfficials":45,"centralContacts":50,"locations":16,"responsibleParty":56,"collaborators":58,"id":61,"slug":16,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":16,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":16,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":16,"overallStatus":80,"whyStopped":16,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":16},{"fullName":5,"class":6},"Jemincare","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"Cmax of JMKX003142 in plasma","Cmax of JMKX003142 when JMKX003142 administered with or without itraconazole\u002Frifampicin","approximately 5 days after JMKX003142 administered",{"measure":14,"description":15,"timeFrame":12},"AUC of JMKX003142 in plasma","AUC of JMKX003142 when JMKX003142 administered with or without itraconazole\u002Frifampicin",null,{"allocation":18,"interventionModel":19,"interventionModelDescription":16,"primaryPurpose":20,"observationalModel":16,"timePerspective":16,"maskingInfo":21},"NON_RANDOMIZED","SINGLE_GROUP","TREATMENT",{"masking":22,"maskingDescription":16,"whoMasked":16},"NONE",[24,30],{"label":25,"type":26,"description":27,"interventionNames":28},"Cohort 1：JMKX003142 and itraconazole","EXPERIMENTAL","Interaction between JMKX003142 and itraconazole",[29],"Drug: Cohort 1: JMKX003142 and itraconazole",{"label":31,"type":26,"description":32,"interventionNames":33},"Cohort 2：JMKX003142 and rifampicin","Interaction between JMKX003142 and rifampicin",[34],"Drug: Cohort 2: JMKX003142 and rifampicin",[36,41],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":16},"DRUG","Cohort 1: JMKX003142 and itraconazole","JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.\n\nItraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD",[25],{"type":37,"name":42,"description":43,"armGroupLabels":44,"otherNames":16},"Cohort 2: JMKX003142 and rifampicin","JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.\n\nRifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD",[31],[46],{"name":47,"affiliation":48,"role":49},"Leilei Zhu","Shuguang Hospital Affiliated with Shanghai University of TCM","PRINCIPAL_INVESTIGATOR",[51],{"name":52,"role":53,"phone":54,"phoneExt":16,"email":55},"Jianping Su","CONTACT","86+15162481262","sujianping@jemincare.com",{"type":57,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR",[59],{"name":60,"class":6},"Zhejiang Hangyu Pharmaceutical Co., Ltd.","100566729",false,"NCT06658964","Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects","A Single-center, Non-randomized, Open-label, Self-controlled Phase 1 Clinical Study to Evaluate Drug-drug Interactions of JMKX003142 Tablets in Healthy Subjects","Inclusion Criteria:\n\n* Fully understand the research content, process, and potential risks of this trial, voluntarily participate in the clinical trial and sign the informed consent,\n* Healthy male and female subjects aged ≥18 years and ≤45 years old, Male weight ≥50kg, female weight ≥45kg, body mass index ≥19 kg\u002Fm2 and ≤28 kg\u002Fm2,\n* The health of the subjects was determined by the investigator based on medical history, physical examination, clinical laboratory examination, and 12-lead electrocardiogram, all of which were determined by the investigator to be normal or not clinically significant.\n\nExclusion Criteria:\n\n* HBV surface antigen, HCV antibody, HIV, or syphilis are positive during screening,\n* At the time of screening, the vital signs are within the following ranges: systolic blood pressure \\\u003C90 mmHg or \\>140 mmHg, diastolic blood pressure \\\u003C50 mmHg or \\>90 mmHg, pulse \\\u003C50 bpm or \\>100 bpm and ear temperature 37.5℃or\\\u003C35℃,\n* More than 5 cigarettes per day during the 3 months prior to screening, Or were unable to quit smoking\u002Fcontaining tobacco products during the trial,\n* Have special requirements for diet and cannot comply with the diet provided and corresponding regulations.",true,"ALL","18 Years","45 Years",{"count":72,"type":73},48,"ESTIMATED","INTERVENTIONAL",[76],"PHASE1","To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of JMKX003142 in healthy subjects.",[79],"ADPKD (autosomal Dominant Polycystic Kidney Disease)","NOT_YET_RECRUITING","2024-10-23",{"date":83,"type":84},"2024-10-26","ACTUAL",{"date":86,"type":73},"2024-11-05",{"date":88,"type":73},"2025-03-21",{"name":5,"class":6}]